AtaGenix Custom Anti-TauN368 Antibody Enables hTau368 Alzheimer’s Model Research and Uncovers the Pathological Role of Truncated Tau

Research Background

Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the elderly, driven by abnormal accumulation of hyperphosphorylated tau protein that forms neurofibrillary tangles (NFTs) and causes cognitive decline. Truncated tau fragments — particularly N1-368 — are significantly elevated in AD patient brains and aged mice, promoting tau pathology progression. To model this mechanism specifically, researchers developed a novel tet-on transgenic mouse model (hTau368) that inducibly expresses truncated human tau N1-368, producing hippocampal tau accumulation, phosphorylation, neuronal loss, and cognitive impairment. The related research was published in Translational Neurodegeneration (2023, DOI: 10.1186/s40035-023-00379-5).

Client Needs

The research team aimed to establish and characterize an accessible AD animal model. They required a monoclonal antibody that could: (1) distinguish truncated tau N1-368 from full-length tau with high specificity and zero cross-reactivity; (2) work reliably across multiple platforms — Western Blot, immunofluorescence (IF), and immunohistochemistry (IHC); (3) detect tau accumulation in specific hippocampal subregions (CA1, DG) with sensitivity sufficient for quantitative analysis; and (4) provide stable, reproducible performance to validate a doxycycline-controlled reversible expression system across multiple experimental timepoints.

Technical Challenges

Developing an antibody against the tau truncation site presented specific difficulties:

• The antibody had to recognize a neo-epitope exposed only at the truncation site (position 368), without binding the same sequence in full-length tau where it is buried within the protein structure.
• Multi-platform compatibility (WB, IF, IHC) required an antibody that performs under both denaturing and native conditions with minimal non-specific background.
• Quantitative detection in hippocampal subregions (CA1 vs. DG) demanded high sensitivity and low lot-to-lot variability.
• The doxycycline-inducible model required the antibody to detect graded levels of truncated tau expression, not just presence/absence.

Customized Solutions

AtaGenix designed a targeted workflow to address each challenge:

• Neo-Epitope Immunogen Design: A KLH-conjugated tau peptide (Cys-358DNITHVPGGGN368) was designed to target the exact truncation site. The N-terminal cysteine enabled oriented conjugation, ensuring the neo-epitope at position 368 was maximally exposed to the immune system.
• Hybridoma Development & Screening: C57BL/6J mice were immunized with the conjugated peptide. Hybridoma cell fusion and iterative subcloning screening identified monoclonal clones with ELISA titers exceeding 1:64,000. Clones were counter-screened against full-length tau to eliminate cross-reactive candidates.
• High-Purity Purification: Antibodies were purified by Protein A/G affinity chromatography to >95% purity (SDS-PAGE verified), with batch consistency testing to ensure reproducible performance across experimental runs.
• Multi-Platform Validation: The anti-tauN368 antibody was validated for WB (recommended dilution 1:1,000) and IF staining in hippocampal sections. The Odyssey imaging system and ImageJ quantification confirmed specific detection of truncated tau aggregates with minimal background. Recommended experimental conditions for each application were provided with the QC report.

Research Outcomes and Impact

With AtaGenix’s anti-tauN368 antibody, the research team successfully validated doxycycline-induced reversible tau accumulation and phosphorylation in the hTau368 hippocampus. The antibody confirmed that truncated tau triggers glial activation, neuronal loss, and synaptic degeneration, directly linking these events to cognitive impairment measured by Morris water maze behavioral testing. Electron microscopy further corroborated synaptic damage. These findings established hTau368 as an accessible, controllable AD model for tau-targeted drug development — a significant advance beyond traditional Aβ-focused approaches. For the client, the project delivered publication-quality data and a validated detection tool for ongoing translational research in tau-targeted therapeutics.

Figure 1. Characterization of the hTau368 transgenic mouse model. Doxycycline-induced expression of truncated human tau N1-368 in the hippocampus, detected and validated using AtaGenix custom anti-tauN368 monoclonal antibody.

Figure 2. Tau accumulation and phosphorylation in hippocampal CA1 and DG subregions. Anti-tauN368 WB and IF analysis confirmed region-specific truncated tau expression, phosphorylation, and reversibility upon doxycycline withdrawal.

This case study is based on a published research collaboration. Results may vary depending on target antigen, antibody format, and experimental conditions. All proprietary client information is subject to NDA. Reference: Zhang Y, et al. Translational Neurodegeneration. 2023. DOI: 10.1186/s40035-023-00379-5